Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Karyopharm Therapeutics Inc. reported revenue of $146M, up 0.6% year over year. Operating margin was -62.1% and net margin -134.2%, on a free-cash-flow margin of -51.6% with capital expenditure at 0.0% of revenue. Every figure is computed directly from KPTI's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $146M | -62.1% | -134.2% |
| FY2024 | $145M | -82.2% | -52.6% |
| FY2023 | $146M | -88.7% | -98.0% |
| FY2022 | $157M | -90.5% | -105.2% |
| FY2021 | $210M | -46.8% | -59.1% |
How does KPTI compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.